on LR Health & Beauty SE (isin : NO0013149658)
LR Health & Beauty SE Reports Mixed First Half of 2026
LR Health & Beauty SE announced a decrease in sales for H1 2026, reaching EUR 118.6 million, down from EUR 142.9 million in the previous year. The company's reported EBITDA also declined to EUR 3.9 million, influenced by a challenging market and restructuring costs.
Despite the setbacks, the company continues its strategic initiatives, focusing on sustainable organizational development and future growth. Important measures include investments at its Ahlen production site and optimizing logistics and international expansion.
CEO Jörg Körfer emphasized the completed financial realignment and upcoming September Business Days as key to deepening community engagement and boosting activities.
Efforts in digitalization and automation also aim to enhance LR's flexibility and scalability in the coming years.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all LR Health & Beauty SE news